Abstract
Background: Sunitinib demonstrated robust antitumor activity in preclinical studies resulting not only in tumor growth inhibition, but tumor regression in models of colon cancer, non-small-cell lung cancer, melanoma, renal carcinoma, and squamous cell carcinoma, which were associated with inhibition of VEGFR and PDGFR phosphorylation.
Aim: The aim of this work is to evaluate the role of Sunitinib as a first line treatment in metastatic Renal Cell Carcinoma (RCC) as regard the response rate, survival outcome and toxicity.
Patients and Methods: This study was conducted at Clinical Oncology and Nuclear Medicine Departments, Tanta University Hospitals and Tanta Cancer Center. All patients with metastatic renal cell carcinoma who treated throughout the period from January 2012 to December 2015 were included. Patient data were retrospectively and personally collected.
Result: All patients were evaluated for tumor response, one (3.3%) of 30 patient had a complete response, 11 (36.7%) patients had a partial response, 6 (20%) patients had a stationary disease and only 12 (40%) had a progressive disease. Median time for treatment failure was 22 months (range 2-34 months). The progression free survival in all patient: the median time was: 22 months 95% CI: 17.5, 27.5 the correlation between PFS and histological types of kidney cancer in which the p-value is <0.001 which is statistically significant in favor of clear renal cell carcinoma. The correlation between OS and MSKCC score in which the p-value is <0.001 which is statis-tically significant. The correlation between OS and histological types in which the p-value is <0.001 which is statistically significant in favor of clear cell carcinoma.
Conclusion: The present study has suggested that Sunitinib was both effective as a first-line treatment and well tolerated in patients with metastatic renal cell carcinoma.